Endocyte and ITM Announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St muted as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 3% as Iran tempers hopes of Hormuz reopening
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Cowen Sees Favorable Risk/Reward in Endocyte (ECYT) Amid Phase III Trial of PSMA-617
February 27, 2018 3:33 PM ESTEndocyte, Inc. (NASDAQ: ECYT) recently announced that the commencement of a pivotal Phase III trial of its leading drug, PSMA-617, a radioligand therapeutic that targets the prostate-specific membrane antigen. This announcement, coming alongside the company's 4Q earnings, has prompted analysts at Cowen to... More
